Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Elucida Oncology

Request full access

Elucida Oncology is focused on transforming outcomes for patients with primary solid tumor and metastatic cancer

New York City, United StatesFounded 2014Biotech & Life Sciences

About Elucida Oncology

Elucida Oncology is a clinical-stage biotechnology company focused on developing advanced cancer therapies. The company operates in the oncology sector, targeting cancer treatment through its innovative ultra-small nanoparticle drug conjugate (CDC) platform. This technology is designed to penetrate deeper into tumors and deliver a significantly higher payload compared to traditional antibody drug conjugates (ADCs). Elucida Oncology's CDCs offer greater avidity for target antigens, longer retention in tumors, and minimal systemic exposure due to rapid renal clearance. The company's business model revolves around pioneering next-generation cancer treatments, aiming to bring these therapies to market through clinical trials and regulatory approvals. Revenue generation is anticipated through the commercialization of these therapies, either independently or through partnerships with larger pharmaceutical companies. Elucida Oncology serves patients with cancer, healthcare providers, and the broader medical community, operating primarily in the biotechnology and pharmaceutical markets.

Source: Dealroom company data

At a glance

Status
Operational
Employees
1
Open positions
None listed
Dealroom signal
26.7/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Biotechnology, Oncology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Technology
Deep Tech
Client focus
B2B

Funding history

3 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
LATE VCOther financing Jun 2023 $23M $220M Undisclosed ↗
SERIES AOther financing Jan 2021 $44M $176M Undisclosed —
Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

Elucida Oncology website traffic

Latest recorded traffic for Elucida Oncology is 300 monthly website visits, down 3.2% over the last three months. Elucida Oncology's team grew 0% over the past year.

Latest monthly visits300 3-month web change-3.2% 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Elucida Oncology in the New York City ecosystem

Live from Dealroom

The Elucida Oncology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Team profiled 4 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇺🇸 United States100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Elucida Oncology on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Elucida Oncology’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.